SEC Company Response from TuHURA Biosciences, (HURA) — Jul 1, 2015
TuHURA Biosciences, Inc./NV (HURA) (CIK 0001498382)
Date: July 1, 2015 · CIK: 0001498382 · Accession: 0001013762-15-000670
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-203357
Letter
DelMar Pharmaceuticals, Inc.
Suite 720-999 West Broadway
Vancouver, British Columbia
July 1,
EDGAR
Division of Corporation Finance
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re: DelMar Pharmaceuticals, Inc.
Registration Statement on Form S-1
File No. 333-203357
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, DelMar Pharmaceuticals, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 1:00 p.m., Eastern Time, on July 2, 2015, or as soon thereafter as possible.
The Company hereby acknowledges the following:
· that should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
· the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
· the Company may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
DelMar Pharmaceuticals, Inc.
By: /s/ Jeffrey Bacha
Name: Jeffrey Bacha Title: Chief Executive Officer
Show Raw Text
CORRESP
1
filename1.htm
DelMar Pharmaceuticals, Inc.
Suite 720-999 West Broadway
Vancouver, British Columbia
July 1,
2015
EDGAR
Division of Corporation Finance
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re: DelMar
Pharmaceuticals, Inc.
Registration Statement on Form S-1
File No. 333-203357
Ladies
and Gentlemen:
Pursuant
to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, DelMar Pharmaceuticals, Inc. (the
“Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated
so that it will become effective at 1:00 p.m., Eastern Time, on July 2, 2015, or as soon thereafter as possible.
The
Company hereby acknowledges the following:
· that should the Commission or the staff, acting pursuant
to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect
to the filing;
· the action of the Commission or the staff, acting pursuant
to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy
and accuracy of the disclosure in the filing; and
· the Company may not assert the declaration of effectiveness
as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
DelMar
Pharmaceuticals, Inc.
By:
/s/ Jeffrey Bacha
Name: Jeffrey Bacha
Title: Chief Executive Officer